source
- Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to oneTakeda has dropped another celiac disease therapy from its phase 2 pipeline, leaving the company with just one shot at treating the condition.Fierce Biotech · 9h ago↗ source
- GSK pens $110M biological datasets pact with AI biotech RelationGSK is boosting its AI chops with a new deal worth up to $110 million with Relation.Fierce Biotech · 10h ago↗ source
- Boston Scientific cuts guidance again after unveiling restructuring planBoston Scientific is cutting its financial guidance for the second quarter in a row as it gears up for a tough six months ahead.Fierce Biotech · 12h ago↗ source